These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8666766)

  • 1. Low incidence of quinolone resistance in gram-negative bacteria after five-years use of ofloxacin in prophylaxis during afebrile neutropenia.
    Kunova A; Trupl J; Krcmery V
    J Hosp Infect; 1996 Feb; 32(2):155-6. PubMed ID: 8666766
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group.
    Bow EJ; Mandell LA; Louie TJ; Feld R; Palmer M; Zee B; Pater J
    Ann Intern Med; 1996 Aug; 125(3):183-90. PubMed ID: 8686975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro assessment of the postantibiotic effect of lomefloxacin against gram-positive and gram-negative pathogens.
    Debbia EA; Pesce A; Schito GC
    Am J Med; 1992 Apr; 92(4A):45S-47S. PubMed ID: 1316070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections.
    Gimeno C; Borja J; Navarro D; Valdés L; García-Barbal J; García-de-Lomas J
    Chemotherapy; 1998; 44(2):94-8. PubMed ID: 9551238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of ofloxacin in infections which do not readily respond to treatment].
    Zalaudek G
    Antibiot Khimioter; 1996; 41(9):11-2. PubMed ID: 9005779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin prophylaxis in neutropenic patients.
    von Baum H; Sigge A; Bommer M; Kern WV; Marre R; Döhner H; Kern P; Reuter S
    J Antimicrob Chemother; 2006 Oct; 58(4):891-4. PubMed ID: 16880172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
    Thomson KS; Sanders CC
    J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?
    Martínez JL; Alonso A; Gómez-Gómez JM; Baquero F
    J Antimicrob Chemother; 1998 Dec; 42(6):683-8. PubMed ID: 10052889
    [No Abstract]   [Full Text] [Related]  

  • 10. In-vitro selection of bacteria resistant to the 4-quinolone agents.
    Limb DI; Dabbs DJ; Spencer RC
    J Antimicrob Chemother; 1987 Jan; 19(1):65-71. PubMed ID: 3470281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review.
    Goldstein MH; Kowalski RP; Gordon YJ
    Ophthalmology; 1999 Jul; 106(7):1313-8. PubMed ID: 10406613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
    Piddock LJ; Panchal S; Norte V
    J Antimicrob Chemother; 1993 Jun; 31(6):855-63. PubMed ID: 8395493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
    D'Antonio D; Piccolomini R; Iacone A; Fioritoni G; Parruti G; Betti S; Quaglietta AM; Accorsi P; Dell'Isola M; Favalli C
    J Antimicrob Chemother; 1994 Apr; 33(4):837-44. PubMed ID: 8056702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Susceptibility in vitro to certain quinolines of gram-negative bacteria and gram-positive cocci causing urinary tract infections].
    Mróz E; Jankowski S; Bartelmus J; Grzybek-Hryncewicz K; Ruczkowska J; Starek J; Boratyńska M
    Med Dosw Mikrobiol; 1993; 45(1):115-8. PubMed ID: 8231429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinolone resistance in neutropenic patients: the effect of prescribing policy in the UK and Pakistan.
    Zaidi Y; Hastings M; Murray J; Hassan R; Kurshid M; Mahendra P
    Clin Lab Haematol; 2001 Feb; 23(1):39-42. PubMed ID: 11422229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antimicrobial activity and action mechanism of ofloxacin].
    Padeĭskaia EN
    Antibiot Khimioter; 1996; 41(9):13-23. PubMed ID: 9005780
    [No Abstract]   [Full Text] [Related]  

  • 18. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects.
    Gootz TD; Brighty KE
    Med Res Rev; 1996 Sep; 16(5):433-86. PubMed ID: 8865150
    [No Abstract]   [Full Text] [Related]  

  • 20. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.